Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In 2009, GRAPPA published their first evidence-based recommendations for the treatment of psoriasis and psoriatic arthritis (PsA). Since then, new information has been published and drugs developed. We summarize evidence for the efficacy of available treatments for peripheral joint involvement in PsA. We performed a systematic review of current literature on the efficacy of different therapies, management, and therapeutic strategies for peripheral arthritis involvement in PsA, in order to provide information for the development of the new GRAPPA treatment recommendations.

Original publication




Journal article


J rheumatol

Publication Date





2277 - 2285


BIOLOGICS, DISEASE MODIFYING ANTIRHEUMATIC DRUGS, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, THERAPEUTIC STRATEGIES, TUMOR NECROSIS FACTOR INHIBITORS, Adrenal Cortex Hormones, Anti-Inflammatory Agents, Non-Steroidal, Antirheumatic Agents, Arthritis, Psoriatic, Biological Products, Comorbidity, Drug Therapy, Combination, Evidence-Based Medicine, Female, Follow-Up Studies, Humans, Injections, Intra-Articular, Joint Diseases, Male, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Severity of Illness Index, Treatment Outcome